{"id":1726,"date":"2024-05-09T10:22:25","date_gmt":"2024-05-09T10:22:25","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=1726"},"modified":"2024-05-09T10:22:25","modified_gmt":"2024-05-09T10:22:25","slug":"accession-therapeutics-raises-25m","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/","title":{"rendered":"Accession Therapeutics raises \u00a325m"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_1887dd9ca02cd454d9d9019d7188c90e\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png 1200w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-300x169.png 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1024x576.png 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-768x432.png 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1000x563.png 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-475x267.png 475w\" type=\"image\/png\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">Accession Therapeutics raises \u00a325m<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n                    <li class=\"arc-purple\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/corporate\/\">Corporate<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p>ARC Oxford member,<a href=\"https:\/\/www.accessiontherapeutics.com\/\" target=\"_blank\" rel=\"noreferrer noopener\"> Accession Therapeutics<\/a> Limited, which is developing novel, first-in-class immunotherapies targeted at tumour sites and administered systemically to provide a step-change in cancer treatment, has raised \u00a325m. This will fund it through the generation of the first clinical data for its lead product TROCEPT-01. The financing, which will also advance its second programme to clinical trial readiness, brings the total funds committed to Accession Therapeutics in the 30 months since operations started to over \u00a350 million. TROCEPT-01 will be the first product generated by Accession Therapeutics\u2019 TROCEPT platform to enter the clinic. The platform is highly tuneable with the ability to administer a variety of potent anti-cancer transgene payloads specifically to tumours.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>As well as providing clinical proof-of-concept of the TROCEPT platform, the proceeds of the fundraising round will enable manufacture of clinical trial material and completion of IND-enabling studies for the next programme, leveraging the efficiencies and experience gained from TROCEPT-01. The internal early-stage pipeline will also be progressed.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Attracted by TROCEPT\u2019s potential to create the ideal immunotherapy, the fundraising round was led by serial backers of CEO Professor Bent Jakobsen\u2019s research-to-clinic leadership. He is a serial entrepreneur in the immunotherapy space and has founded public biotech companies.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1000\" height=\"667\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/bent_jakons.jpg\" alt=\"\" class=\"wp-image-1728\" srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/bent_jakons.jpg 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/bent_jakons-300x200.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/bent_jakons-768x512.jpg 768w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">Accession Therapeutics CEO Professor Bent Jakobsen<\/figcaption><\/figure>\n<\/div>\n\n\n<p><\/p>\n\n\n\n<p>Lead product TROCEPT-01 encodes a clinically validated immune checkpoint inhibitor as the payload that will be produced and secreted by cancer cells. It has the potential to expand the indications where checkpoint inhibitors have been successful and increase cancer response rates through high tumour-localised production of the drug where it is needed. It has shown very encouraging data in its IND-enabling studies.\u00a0TROCEPT-01 is expected to enter the clinic in 2024 for multiple significant solid tumour indications (such as non-small cell lung, bladder, head and neck, and pancreatic cancers). The second TROCEPT programme, which encodes an extremely potent universal bispecific immune activator, is expected to start clinical trials a year later.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Bent Jakobsen, PhD FMedSci, CEO of Accession Therapeutics, said, \u2018We\u2019re delighted that our swift evolution into a clinical stage company is being financed by our long-term investors. \u00a0Accession Therapeutics thanks them for their support which will enable us to demonstrate the huge clinical and commercial potential of the TROCEPT platform via our first clinical data.\u2019<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Stay Up to date with the latest ARC news on our social media. <\/p>\n\n\n\n<ul class=\"wp-block-social-links aligncenter is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-linkedin  wp-block-social-link\"><a href=\"https:\/\/uk.linkedin.com\/company\/arcgroup-io\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19.7,3H4.3C3.582,3,3,3.582,3,4.3v15.4C3,20.418,3.582,21,4.3,21h15.4c0.718,0,1.3-0.582,1.3-1.3V4.3 C21,3.582,20.418,3,19.7,3z M8.339,18.338H5.667v-8.59h2.672V18.338z M7.004,8.574c-0.857,0-1.549-0.694-1.549-1.548 c0-0.855,0.691-1.548,1.549-1.548c0.854,0,1.547,0.694,1.547,1.548C8.551,7.881,7.858,8.574,7.004,8.574z M18.339,18.338h-2.669 v-4.177c0-0.996-0.017-2.278-1.387-2.278c-1.389,0-1.601,1.086-1.601,2.206v4.249h-2.667v-8.59h2.559v1.174h0.037 c0.356-0.675,1.227-1.387,2.526-1.387c2.703,0,3.203,1.779,3.203,4.092V18.338z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">LinkedIn<\/span><\/a><\/li>\n\n<li class=\"wp-social-link wp-social-link-instagram  wp-block-social-link\"><a href=\"https:\/\/www.instagram.com\/arcgroup.io\/\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M12,4.622c2.403,0,2.688,0.009,3.637,0.052c0.877,0.04,1.354,0.187,1.671,0.31c0.42,0.163,0.72,0.358,1.035,0.673 c0.315,0.315,0.51,0.615,0.673,1.035c0.123,0.317,0.27,0.794,0.31,1.671c0.043,0.949,0.052,1.234,0.052,3.637 s-0.009,2.688-0.052,3.637c-0.04,0.877-0.187,1.354-0.31,1.671c-0.163,0.42-0.358,0.72-0.673,1.035 c-0.315,0.315-0.615,0.51-1.035,0.673c-0.317,0.123-0.794,0.27-1.671,0.31c-0.949,0.043-1.233,0.052-3.637,0.052 s-2.688-0.009-3.637-0.052c-0.877-0.04-1.354-0.187-1.671-0.31c-0.42-0.163-0.72-0.358-1.035-0.673 c-0.315-0.315-0.51-0.615-0.673-1.035c-0.123-0.317-0.27-0.794-0.31-1.671C4.631,14.688,4.622,14.403,4.622,12 s0.009-2.688,0.052-3.637c0.04-0.877,0.187-1.354,0.31-1.671c0.163-0.42,0.358-0.72,0.673-1.035 c0.315-0.315,0.615-0.51,1.035-0.673c0.317-0.123,0.794-0.27,1.671-0.31C9.312,4.631,9.597,4.622,12,4.622 M12,3 C9.556,3,9.249,3.01,8.289,3.054C7.331,3.098,6.677,3.25,6.105,3.472C5.513,3.702,5.011,4.01,4.511,4.511 c-0.5,0.5-0.808,1.002-1.038,1.594C3.25,6.677,3.098,7.331,3.054,8.289C3.01,9.249,3,9.556,3,12c0,2.444,0.01,2.751,0.054,3.711 c0.044,0.958,0.196,1.612,0.418,2.185c0.23,0.592,0.538,1.094,1.038,1.594c0.5,0.5,1.002,0.808,1.594,1.038 c0.572,0.222,1.227,0.375,2.185,0.418C9.249,20.99,9.556,21,12,21s2.751-0.01,3.711-0.054c0.958-0.044,1.612-0.196,2.185-0.418 c0.592-0.23,1.094-0.538,1.594-1.038c0.5-0.5,0.808-1.002,1.038-1.594c0.222-0.572,0.375-1.227,0.418-2.185 C20.99,14.751,21,14.444,21,12s-0.01-2.751-0.054-3.711c-0.044-0.958-0.196-1.612-0.418-2.185c-0.23-0.592-0.538-1.094-1.038-1.594 c-0.5-0.5-1.002-0.808-1.594-1.038c-0.572-0.222-1.227-0.375-2.185-0.418C14.751,3.01,14.444,3,12,3L12,3z M12,7.378 c-2.552,0-4.622,2.069-4.622,4.622S9.448,16.622,12,16.622s4.622-2.069,4.622-4.622S14.552,7.378,12,7.378z M12,15 c-1.657,0-3-1.343-3-3s1.343-3,3-3s3,1.343,3,3S13.657,15,12,15z M16.804,6.116c-0.596,0-1.08,0.484-1.08,1.08 s0.484,1.08,1.08,1.08c0.596,0,1.08-0.484,1.08-1.08S17.401,6.116,16.804,6.116z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Instagram<\/span><\/a><\/li><\/ul>\n\n\n    <section class=\"news-archive \" id=\"block_23f00c252576e03d139d8585d37cc034\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png 1200w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-300x169.png 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1024x576.png 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-768x432.png 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1000x563.png 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-475x267.png 475w\" type=\"image\/png\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\" target=\"_self\">\n\t\t\t\tAccession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg 1110w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-300x201.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1024x685.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-768x513.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1000x668.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\" target=\"_self\">\n\t\t\t\tChildbase Partnership announces new Garsington Road day nursery opening at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg 2402w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-300x200.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1024x682.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-768x512.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1000x666.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\" target=\"_self\">\n\t\t\t\tOxa Raises $103m in Series D First Close to supercharge Industrial Mobility Automation\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>ARC Oxford member, Accession Therapeutics Limited, which is developing novel, first-in-class immunotherapies targeted at tumour sites and administered systemically to provide a step-change in cancer treatment, has raised \u00a325m. This will fund it through the generation of the first clinical data for its lead product TROCEPT-01. The financing, which will also advance its second programme [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":1727,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22,30],"tags":[6210],"class_list":["post-1726","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-corporate","tag-life-science-and-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Accession Therapeutics raises \u00a325m - ARC Oxford<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accession Therapeutics raises \u00a325m - ARC Oxford\" \/>\n<meta property=\"og:description\" content=\"ARC Oxford member, Accession Therapeutics Limited, which is developing novel, first-in-class immunotherapies targeted at tumour sites and administered systemically to provide a step-change in cancer treatment, has raised \u00a325m. This will fund it through the generation of the first clinical data for its lead product TROCEPT-01. The financing, which will also advance its second programme [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-09T10:22:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"rebeccabethwaite\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rebeccabethwaite\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/\"},\"author\":{\"name\":\"rebeccabethwaite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57\"},\"headline\":\"Accession Therapeutics raises \u00a325m\",\"datePublished\":\"2024-05-09T10:22:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/\"},\"wordCount\":390,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\",\"keywords\":[\"Life science and Health\"],\"articleSection\":[\"News\",\"Corporate\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/\",\"name\":\"Accession Therapeutics raises \u00a325m - ARC Oxford\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\",\"datePublished\":\"2024-05-09T10:22:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\",\"width\":1200,\"height\":675,\"caption\":\"ARC Oxford Member, Accession Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/oxford\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accession Therapeutics raises \u00a325m\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57\",\"name\":\"rebeccabethwaite\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g\",\"caption\":\"rebeccabethwaite\"},\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/rebeccafrost\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accession Therapeutics raises \u00a325m - ARC Oxford","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/","og_locale":"en_US","og_type":"article","og_title":"Accession Therapeutics raises \u00a325m - ARC Oxford","og_description":"ARC Oxford member, Accession Therapeutics Limited, which is developing novel, first-in-class immunotherapies targeted at tumour sites and administered systemically to provide a step-change in cancer treatment, has raised \u00a325m. This will fund it through the generation of the first clinical data for its lead product TROCEPT-01. The financing, which will also advance its second programme [&hellip;]","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/","og_site_name":"ARC Oxford","article_published_time":"2024-05-09T10:22:25+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","type":"image\/png"}],"author":"rebeccabethwaite","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rebeccabethwaite","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/"},"author":{"name":"rebeccabethwaite","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57"},"headline":"Accession Therapeutics raises \u00a325m","datePublished":"2024-05-09T10:22:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/"},"wordCount":390,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","keywords":["Life science and Health"],"articleSection":["News","Corporate"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/","name":"Accession Therapeutics raises \u00a325m - ARC Oxford","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","datePublished":"2024-05-09T10:22:25+00:00","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png","width":1200,"height":675,"caption":"ARC Oxford Member, Accession Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2024\/05\/09\/accession-therapeutics-raises-25m\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"Accession Therapeutics raises \u00a325m"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/3a1b3eb8a7bd2232ae3f80a34598bd57","name":"rebeccabethwaite","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ee39d695ce12a74184723b0a62162c291da18c1d7878213e161c04e87289ce2?s=96&d=mm&r=g","caption":"rebeccabethwaite"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/rebeccafrost\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/1726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=1726"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/1726\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/1727"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=1726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=1726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=1726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}